LOGIN  |  REGISTER

Cue Health to Present at Upcoming Investor Conferences

August 23, 2023 | Last Trade: US$0.04 0.00 0.00

SAN DIEGO / Aug 23, 2023 / Business Wire / Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the following investor conferences:

  • 2023 Wells Fargo Healthcare Conference

    Presenting via fireside chat on Wednesday, September 6, 2023 at 3:00 p.m. Eastern Time in Boston, MA at the Encore Boston Harbor
  • Morgan Stanley 21st Annual Global Healthcare Conference

    Presenting via fireside chat on Monday, September 11, 2023 at 2:55 p.m. Eastern Time in New York, NY at the Sheraton New York

The live audio webcasts and replays of the presentations may be accessed on the “Investor Relations” section of the company’s website at: https://cuehealth.com/.

About Cue Health

Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. The Cue Health platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point of care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue’s customers include federal and state public sector agencies and the private sector, which includes healthcare providers, enterprises, and individual consumers. Cue’s COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription. Cue has since received Emergency Use Authorization from the FDA for its molecular mpox test at the point of care and, to expand its test menu, the company has a number of other submissions under review by the FDA. Cue, founded in 2010, owns over 100 patents and is headquartered in San Diego. For more information, please visit www.cuehealth.com.

Astria Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB